Research in the Annals of the Rheumatic Diseases found no difference in efficacy, safety or immunogenicity when switching from Humira, or adalimumab, to the FDA-approved biosimilar Cyltezo, from Boehringer Ingelheim.
Switch to biosimilar referencing Humira is safe and effective, study shows
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.